What Purity Should PT-141 Be?

Quick answer: What is the analytical purity standard for PT-141?

In analytical biochemistry and preclinical research, synthetic PT-141 (Bremelanotide) should meet a minimum purity threshold of 98.0% peak area purity via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). Purity levels below 98.0% indicate the presence of synthesis byproducts, truncation sequences, or degradation fragments that can skew receptor-binding affinity data.

Crucially, chromatographic purity is distinct from net peptide content. While the RP-HPLC chromatogram verifies that 98%+ of the peptide material consists of the target sequence, the actual peptide mass in a vial accounts for 80% to 90% of total lyophilized weight due to residual trifluoroacetic acid (TFA) salts and bound moisture.

To guarantee experimental reproducibility in cellular and animal models, investigators must confirm sequence mass identity (theoretical molecular weight of 1024.18 Da via ESI-MS) and verify that bacterial endotoxin levels remain below 0.05 EU/mg. PX1 Research publishes lot-specific analytical reports for every batch of lyophilized PT-141 10 mg to validate these criteria before shipment.

What is PT-141 and how is its molecular identity established?

PT-141, chemically known as Bremelanotide, is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). Its primary primary structure consists of the amino acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. As a selective melanocortin agonist, PT-141 is primarily investigated for its activation of melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptor signaling pathways linked to central nervous system regulation of sexual-health pathways.

Establishing the precise identity of PT-141 requires confirming both its primary sequence and its lactam bridge cyclization. Linear pre-peptides that fail to cyclize correctly between the Asp and Lys residues exhibit different retention times and reduced biological activity in receptor assays.

Mass spectrometry—specifically Electrospray Ionization Mass Spectrometry (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF)—is the primary method used to confirm structural identity. The calculated monoisotopic molecular mass of PT-141 is 1024.18 Da. A valid mass spectrum must show a prominent singly charged ion peak [M+H]+ at m/z 1025.2 or a doubly charged peak [M+2H]2+ at m/z 513.1, with an absence of deletion sequences. For detailed literature on sequence chemistry, review our dedicated PT-141 research guide.

Why RP-HPLC peak integration determines PT-141 purity percentage

Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) is the standard method for determining the chemical purity of synthetic peptides. The assay separates the target molecule from synthetic impurities based on hydrophobic interactions with a C18 stationary phase using a mobile phase gradient (typically water and acetonitrile with 0.1% TFA counter-ion buffer).

When evaluating a PT-141 HPLC chromatogram, the analytical software integrates the area under all detected UV absorption peaks (usually monitored at 214 nm, the absorption wavelength of the peptide amide backbone). The purity percentage is calculated by dividing the peak area of PT-141 by the total integrated peak area across the entire elution run:

Purity % = (Peak Area of Target Peptide / Sum of All Integrated Peak Areas) × 100

A threshold of ≥98.0% ensures that deletion peptides (missing single amino acids like D-Phe or Trp), oxidized impurities (such as tryptophan oxidation), and diastereomers generated during solid-phase peptide synthesis (SPPS) are minimized. High chromatographic purity is essential when mapping receptor binding kinetics, as closely related peptide impurities can competitively inhibit target receptors or cause off-target signaling artifact.

Understanding net peptide content versus gross label mass

A common point of confusion among laboratory researchers is the difference between the labeled powder mass in a vial (e.g., 10 mg) and the net peptide content. Synthetic peptides produced via SPPS undergo cleavage and purification steps utilizing trifluoroacetic acid (TFA). Because basic amino acid residues (such as Lysine and Arginine) contain positively charged side chains, they form salts with TFA anions.

As a result, a lyophilized cake containing 10 mg of total dry powder is not 100% pure peptide by weight. The composition typically breaks down as follows:

1. Pure PT-141 Peptide Sequence: 80% to 88% of total mass. 2. TFA Counter-Ions (Salt Weight): 10% to 15% of total mass. 3. Residual Volatiles and Hydration Water: 2% to 6% of total mass.

If an experiment requires precise molar concentration (e.g., a 10 micromolar in vitro receptor binding assay), calculating the dosage using gross powder weight without accounting for net peptide content will result in under-dosing by 12% to 20%. PX1 Research provides clear net peptide content determinations on third-party COAs so researchers can accurately calibrate stock solution concentrations when using our 10 mg vials of PT-141.

Endotoxin thresholds and residual solvent standards for PT-141

For cell-culture assays, organoid studies, and animal model research, total chemical purity is only part of the quality specification. Bacterial endotoxins—lipopolysaccharides (LPS) shed from Gram-negative bacteria during synthesis or purification—can trigger powerful inflammatory pathways, activating Toll-like receptor 4 (TLR4) independently of melanocortin receptor activation.

When endotoxins contaminate PT-141 samples, experimental observations regarding vascular response or central signaling can be invalidated by underlying immune reactions. Laboratory-grade PT-141 must undergo Limulus Amebocyte Lysate (LAL) testing according to USP <85> guidelines.

Acceptable endotoxin limits for research-grade peptides are established below 0.05 EU/mg. Furthermore, residual solvents used during peptide cleavage (such as acetonitrile, dichloromethane, and piperidine) must be removed via evaporative lyophilization to levels meeting USP <467> residual solvent safety limits.

How to read a PT-141 Certificate of Analysis step by step

A authentic Certificate of Analysis (COA) is the primary document validating peptide specifications. Researchers should inspect COAs systematically across five critical sections before reconstituting any material:

1. Analytical Header & Lot Traceability: Verify that the product name (PT-141 / Bremelanotide), chemical formula (C50H68N14O10), and exact lot number match the physical label on the vial. Cross-reference the analysis date to ensure freshness.

2. RP-HPLC Chromatogram & Data Table: Examine the visual chromatogram. Look for a sharp, narrow main peak corresponding to PT-141 around the recorded retention time. Review the data table below the trace: the integrated peak area for the main peak must explicitly state ≥98.0%. Inspect baseline stability for hidden secondary peaks.

3. Electrospray Mass Spectrum (ESI-MS): Check the mass-to-charge ratio (m/z) spectral plot. Confirm that the dominant observed molecular mass matches the theoretical mass (1024.18 Da) within standard instrument tolerance (± 1 Da).

4. Endotoxin Quantification: Ensure a quantitative LAL assay value is reported in EU/mg (e.g., <0.01 EU/mg) rather than a simple 'pass/fail' marker.

5. Physical Appearance & Solubility: Confirm description notes (e.g., 'White lyophilized powder') and solubility verification in sterile water or phosphate-buffered saline (PBS).

Red flags when vetting research peptide suppliers

The supply market for research compounds contains significant quality variation. Obtaining reproducible analytical data requires identifying and avoiding common vendor red flags:

• Reused or Static COAs: Vendors displaying generic COA images without lot numbers, or presenting identical chromatograms across multiple distinct batches, are not performing real-time lot testing.

• Missing Raw HPLC Traces: Providing only a text table with '99% Purity' without the accompanying raw chromatographic trace and baseline integration table makes independent verification impossible.

• Absence of Endotoxin Testing: Omitting LAL testing data leaves researchers vulnerable to severe LPS contamination in cell and tissue cultures.

• False Claims of '100% Purity': Chemically, no synthesized peptide exists at 100.0% purity due to thermodynamic limitations in SPPS and natural TFA salt equilibria. Claims of 100% reflect fraudulent marketing rather than rigorous science.

• Non-Traceable Sourcing: Suppliers unable to demonstrate USA-based analytical validation or clear batch-tracking protocols pose high risks of compound cross-contamination.

Analytical criteria summary for research peptides

When benchmarking suppliers across the PX1 Research catalog, demand verifiable quantitative metrics across all core performance criteria:

• Purity Verification: Mandatory RP-HPLC testing achieving ≥98.0% integrated peak area.

• Structural Identity Confirmation: ESI-MS or MALDI-TOF confirmation matching target molecular weight (1024.18 Da for PT-141).

• Lot Traceability: Individual lot numbers printed on vial labels matching independent third-party COA documentation.

• Endotoxin Control: Quantitative LAL assay reporting endotoxin content <0.05 EU/mg.

• Net Peptide Content Transparency: Clear reporting of peptide content versus TFA counter-ion/moisture mass.

• Logistics & Stability: Same-day dispatch in temperature-controlled packaging from domestic US hubs to prevent ambient heat degradation during transit.

Comparing PT-141 to related melanocortin signaling compounds

In neuroendocrine and receptor selectivity research, PT-141 is frequently analyzed alongside other structural analogs within the melanocortin agonist family.

For instance, Melanotan II 10 mg shares a similar cyclic heptapeptide core but exhibits non-selective binding across MC1R, MC3R, MC4R, and MC5R receptors. PT-141 was synthetically modified from Melanotan II by removing the lipophilic aromatic side chain to reduce peripheral MC1R melanocyte activation while preserving central MC3R/MC4R signaling specificity.

Researchers investigating broader autonomic or central neuropeptide pathways often evaluate PT-141 in conjunction with non-melanocortin peptides such as Oxytocin 5 mg. Maintaining standardized ≥98% purity across all test compounds ensures that observed cross-talk or receptor synergy is attributable solely to the active sequences under evaluation.

Ordering verified PT-141 from PX1 Research

PX1 Research serves university laboratories, contract research organizations (CROs), and independent scientists who require rigorous analytical validation and reliable supply chains. Every batch of our PT-141 undergoes comprehensive third-party testing in accredited USA facilities prior to catalog release.

What you receive with your order:

• Secure 10 mg Lyophilized Vials: Sealed under vacuum in borosilicate glass vials with flip-off crimp seals to ensure long-term stability.

• Instant COA Access: Lot-specific analytical certificates including HPLC chromatograms, mass spectra, and endotoxin data are fully accessible online.

• Accelerated Dispatch: Orders placed before 3:00 PM EST Monday through Friday ship same-day from our California or Arizona distribution centers.

• Dedicated Support: Technical support specialists available to assist with analytical interpretation and documentation requirements.

Ready to source analytical-grade materials for your laboratory? Visit our product page to inspect live COAs and order 10 mg vials of PT-141 directly.